<DOC>
	<DOCNO>NCT01469052</DOCNO>
	<brief_summary>The purpose study characterize safety investigational agent AG-013736 , patient solid tumor First In Human trial .</brief_summary>
	<brief_title>First In Human , Phase 1 Study AG013736 In Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients cytologically histologically confirm solid tumor ( ) least one measurable disease site Patients adequate bone marrow , liver kidney function Patients life expectancy least 12 week Patients receive chemotherapy , immunotherapy , radiotherapy investigational agent within 4 week study entry Patients major surgical procedure within 4 week study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>